TrialHuman vaccines & immunotherapeutics2024

Safety and immunogenicity of a SARS-CoV-2 recombinant protein subunit vaccine adjuvanted with Alum + CpG 1018 in healthy Indonesian adults: A multicenter, randomized, comparative, observer-blind, placebo-controlled phase 2 study.

Martira Maddeppungeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.